Phase 2 Study of ATH434 in MSA - α-Synuclein Aggregation, Imaging Biomarkers, and Severity

Dr. Margaret Bradbury of Alterity Therapeutics explains how a multimodal approach to diagnosis of multiple system atrophy (MSA) impacts and improves clinical trial research.